| Net revenues | 16,544a | 15,846a | 14,925a |
| Cost of sales | -8,481a | -8,200a | -7,952a |
| Gross profit | 8,064a | 7,645a | 6,973a |
| Research and development expenses, net | -998a | -953a | -838a |
| Selling and marketing expenses | -2,541a | -2,336a | -2,265a |
| General and administrative expenses | -1,161a | -1,162a | -1,180a |
| Intangible assets impairments | -251a | -350a | -355a |
| Goodwill impairment | -1,280a | -700a | -2,045a |
| Other asset impairments, restructuring and other items | -1,388a | -718a | -512a |
| Legal settlements and loss contingencies | -761a | -1,043a | -2,082a |
| Other loss (income) | -14a | -49a | -107a |
| Operating income (loss) | -303a | 433a | -2,197a |
| Financial expenses - net | -981a | -1,057a | -966a |
| Income (loss) before income taxes | -1,284a | -624a | -3,163a |
| Income taxes (benefit) | -676a | -7a | -643a |
| Share in (profits) losses of associated companies - net | -1a | -2a | -21a |
| Net income (loss) | -1,959a | -615a | -2,499a |
| Net income (loss) attributable to non-controlling interests | -320a | -56a | -53a |
| Net income (loss) attributable to Teva | -1,639a | -559a | -2,446a |